GlassScriptPhysician profile
Shawn Wayne Coffman
NPI 1720022643
$9,705.54
in general payments reported to CMS, 2019-2025
48 companies · $790 in 2025
The $790 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,830 · 2020: $1,085 · 2021: $1,694 · 2022: $1,428 · 2023: $1,021 · 2024: $858 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,669.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $999.31 | 2021-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $931.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $795.90 | 2019-2025 | |
| Novo Nordisk INC | $699.36 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $656.82 | 2019-2024 | Farxiga, Breztri, Lokelma |
| Paratek Pharmaceuticals, INC. | $656.10 | 2022-2025 | Nuzyra, Xhance |
| Janssen Pharmaceuticals, INC | $562.98 | 2019-2022 | |
| Amgen INC. | $442.92 | 2019-2022 | |
| Pfizer INC. | $436.98 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $430.14 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $369.19 | 2019-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $324.35 | 2022-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.27 | 2019-2022 | |
| Amarin Pharma, INC. | $287.84 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.78 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Coffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.